Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX-A-DVS: Dense vs Standard XELOX + Bevacizumab in mCRC
NCT00118755Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2005
- Primary completion
- Apr 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free Survival. Started Jul 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00118755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118755.